An observational study in Paraplegia and Hemiplegia, sponsored by University Hospital, Lille. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-12.
Sponsored by University Hospital, Lille · Observational
Among 24 studies in Paraplegia with a site in France — 3 open to participants now, 4 under way, none of them phase 3. Paraplegia · France.
Among the 24 studies in Paraplegia with a site in France, this one is the 8th largest by enrollment of the 10 observational ones that give a count, is one of 3 that started in 2018, is one of 10 observational ones, and was the 10th registered.
151 studies on the registry are indexed under Paraplegia; 36 are open to participants now.
Browse Paraplegia studies →3 of the 24 studies in Paraplegia with a site in France are open now. Recruiting first, the newest first:
Wandercraft · Sites in France
Ages 18+
Central Hospital, Nancy, France · Sites in France
Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de Kerpape · Sites in France
Ages 18–75
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 32 Paraplegia studies recruiting now, 15 (47%) set no upper age limit and 14 (44%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 45 across 32 observational studies indexed under Paraplegia.
Median enrollment 12 across the 14 interventional studies, 48 across the 10 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 24 have an industry lead sponsor. The 10 most frequent:
University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
University Hospital, Lille has 1 study filed under Paraplegia — fewer than ten, so there is no comparison to draw.
1 of the studies in Paraplegia with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07828912Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de KerpapePersonal Exoskeleton or Manual Wheelchair: a Comparison of Performance and Satisfaction in Activities of Daily Living Among People With Spinal Cord Injuries, Using the SCED Methodology. | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Paraplegia with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Power assisted wheelchairs have specific advantages compared to manual propelled or powered Wheelchair. Autonomad Mobility has developed a new device (DUO), the assistance being triggered by the motion of the wheelchair and not an push on the hand rim, people who use their foot to move or people pushing the wheelchair can be helped by the device as people propelling the wheelchair with their arms.
Furthermore DUO has an option with a longer assistance (AEP+) which can be preferred by some people.
To be referenced and reimbursed by the French health insurance, DUO has to be compared with an other power assistance device for wheelchairs, already referenced.
The study is a comparative study between DUO and the ALBER E Motion. Each patient is his own control and is assessed in 4 experimental conditions, with intervals of 3 or 4 days, manually propelled, with the E mtion device, with the DUO device and the single push configuration, with the DUO device and the AEP+ configuration.
The main outcome measure will be the user's satisfaction (using 8 items of the ESAT questionnaire)
Patient with a motor deficiency (of any origin) needing a manual wheelchair
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient in wheelchair with E-motion device
Device: E-motion device
Powered assisted Wheelchair with the E-motion device. Outdoor and indoor runs
ESAT questionnaire
User satisfaction, using 8 items of the ESAT (Echelle de Satisfaction envers une Aide Technique) questionnaire
Time frame: at 12 days
Success rate during the indoor test (wheelchair skill program)
Time frame: at 12 days
Time to perform the wheelchair skill program
Time frame: at 12 days
Time run
During a 500 m outdoor run
Time frame: at 12 days
Maximal heart rate
During a 500 m outdoor run
Time frame: at 12 days
Effort assessment by the Borg scale
During a 500 m outdoor run The 10-point Borg scale ranges from 0 "nothing at all" to 10 "maximal/extremely strong" and will be used to rate the intensity of dyspnea
Time frame: at 12 days
Ran from Mar 2018 to primary completion in Apr 2021, 37 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.